KALY Adds New CBD Extraction Contract Worth $10 Million In Annual Revenue
July 09 2019 - 11:22AM
InvestorsHub NewsWire
KALY Adds New CBD Extraction
Contract Worth $10 Million In Annual Revenue
Dallas, TX -- July 9, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced a second hemp derived CBD
extraction contract worth $10 million in annual revenue. KALY
has previously announced a contract with a New York State Licensed
Hemp Cultivation Operation anticipated to generate an estimated $5
million in revenue for KALY. Management has set a 2019 $20
million CBD extraction target. The contract announced today
is with Nouveau, Inc. (USOTC:
NOUV) (“NOUV”). NOUV has just announced a 100
acre hemp cultivation operation.
KALY Pharma Business and
PURA and USMJ Partnerships
KALY is primarily a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from a proprietary cannabinoid
product platform in a broad range of disease areas. In the fourth
quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). In
NCMB’s four years of operations, the company has established a
leading position in the development of plant-derived cannabinoid
therapeutics through a proven drug discovery and patented
development process. The resulting intellectual property
portfolio and the established regulatory and manufacturing
expertise have created a significant opportunity. KALY has a
deep pipeline of cannabinoid product candidates including four
distinct compounds. KALY has completed the first stage of
clinical development and testing for a Chronic Obstructive
Pulmonary Disease (COPD) therapy and is currently conducting phase
one development and trials for compounds targeting Cancer Pain
Management, Type 2 Diabetes and Epilepsy.
KALY is not relying on its biopharmaceutical development strategy
alone to insure the company’s long-term success. With the
popularity of cannabis extracts for infusion into various consumer
products, KALY’s patented extraction process offers arguably the
highest quality extract to the infusion market. Drawing on
KALY’s patented cannabis extraction expertise, in addition to
winning the $5 million extraction contract mentioned above, KALY
has partnered with Puration, Inc. (PURA)
to lend its extraction expertise in the production of EVERx CBD
Sports Water, the leading CBD infused beverage for the sports
nutrition market. KALY has also introduced its own CBD
confections line, Hemp4mula with CBD infused gum already on the
market and gummies on the way. Hemp4mula is available on the
Ecommerce site USMJ.com hosted by North American Cannabis Holdings,
Inc. (aka
USMJ). KALY’s non-pharmaceutical extraction revenue strategy
offers a business line that can stand alone, and at the same time
provide KALY with the long-term staying power to bring its cannabis
extract biopharmaceutical products to
market.
To learn more about the company
visit https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Jul 2024 to Aug 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2023 to Aug 2024